title: Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
abstract: OBJECTIVE
  Dynamic positron emission tomography (PET) imaging can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC) that are predictive of response. This analysis examines tumor metabolism and perfusion by tumor subtype.
  
  
  METHODS
  Tumor subtype was defined by immunohistochemistry in 71 patients with locally advanced breast cancer undergoing NC. Subtype was defined as luminal [estrogen receptor (ER)/progesterone receptor (PR) positive], triple negative [TN; ER/PR negative, human epidermal growth factor receptor 2 (HER2) negative], and HER2 (ER/PR negative, HER2 overexpressing). Metabolic rate (MRFDG) and blood flow (BF) were calculated from PET imaging before NC. Pathologic complete response (pCR) to NC was classified as pCR versus other.
  
  
  RESULTS
  Twenty-five (35%) of 71 patients had TN tumors; 6 (8%) were HER2 and 40 (56%) were luminal. MRFDG for TN tumors was on average 67% greater than for luminal tumors (95% confidence interval, 9-156%) and average MRFDG/BF ratio was 53% greater in TN compared with luminal tumors (95% confidence interval, 9-114%; P<0.05 for both). Average BF levels did not differ by subtype (P=0.73). Most luminal tumors showed relatively low MRFDG and BF (and did not achieve pCR); high MRFDG was generally matched with high BF in luminal tumors and predicted pCR. This was not true in TN tumors.
  
  
  CONCLUSIONS
  The relationship between breast tumor metabolism and perfusion differed by subtype. The high MRFDG/BF ratio that predicts poor response to NC was more common in TN tumors. Metabolism and perfusion measures may identify subsets of tumors susceptible and resistant to NC and may help direct targeted therapy.
authors.affiliation: Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA. jspecht@uw.edu
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Specht
authors.forename: Brenda F
authors.initials: BF
authors.lastname: Kurland
authors.forename: Susan K
authors.initials: SK
authors.lastname: Montgomery
authors.forename: Lisa K
authors.initials: LK
authors.lastname: Dunnwald
authors.forename: Robert K
authors.initials: RK
authors.lastname: Doot
authors.forename: Julie R
authors.initials: JR
authors.lastname: Gralow
authors.forename: Georgina K
authors.initials: GK
authors.lastname: Ellis
authors.forename: Hannah M
authors.initials: HM
authors.lastname: Linden
authors.forename: Robert B
authors.initials: RB
authors.lastname: Livingston
authors.forename: Kimberly H
authors.initials: KH
authors.lastname: Allison
authors.forename: Erin K
authors.initials: EK
authors.lastname: Schubert
authors.forename: David A
authors.initials: DA
authors.lastname: Mankoff
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D049268:Positron-Emission Tomography; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
references.citation: J Nucl Med. 2002 Apr;43(4):500-9
references.pmid: 11937594
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references.pmid: 12829800
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Radiol Clin North Am. 2005 Jan;43(1):121-34
references.pmid: 15693652
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1160-7
references.pmid: 19204204
references.citation: Cancer Res. 1986 May;46(5):2578-81
references.pmid: 3697997
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5294-6
references.pmid: 19706819
references.citation: J Clin Oncol. 2011 Mar 10;29(8):1014-21
references.pmid: 21220618
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5678-85
references.pmid: 16115903
references.citation: J Natl Cancer Inst. 1958 Dec;21(6):1039-63
references.pmid: 13611531
references.citation: Ann Biomed Eng. 2000 Aug;28(8):922-9
references.pmid: 11144676
references.citation: Acad Radiol. 2008 Oct;15(10):1246-54
references.pmid: 18790395
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5511-7
references.pmid: 19706808
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references.pmid: 18250347
references.citation: Arch Surg. 1989 Jan;124(1):21-5
references.pmid: 2910244
references.citation: J Nucl Med. 1986 Feb;27(2):235-8
references.pmid: 3712040
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2196-201
references.pmid: 16452162
references.citation: BMC Cancer. 2007 Nov 01;7:203
references.pmid: 17976237
references.citation: J Nucl Med. 2004 Nov;45(11):1829-37
references.pmid: 15534051
references.citation: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references.pmid: 17438091
references.citation: J Appl Physiol (1985). 2004 Jul;97(1):404-15
references.pmid: 15220323
references.citation: Cancer Imaging. 2008 Mar 25;8:81-6
references.pmid: 18390391
references.citation: J Nucl Med. 2003 Nov;44(11):1806-14
references.pmid: 14602864
references.citation: Mol Imaging Biol. 2008 Nov-Dec;10(6):356-63
references.pmid: 18709508
references.citation: Nat Clin Pract Oncol. 2008 Mar;5(3):149-59
references.pmid: 18212769
references.citation: Lancet Oncol. 2007 Mar;8(3):235-44
references.pmid: 17329194
references.citation: Cancer. 1997 Nov 1;80(9):1803-4
references.pmid: 9351551
references.citation: Semin Nucl Med. 2009 Jan;39(1):36-51
references.pmid: 19038599
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: J Clin Oncol. 2008 Sep 20;26(27):4449-57
references.pmid: 18626006
references.citation: Cancer. 2008 Mar 1;112(5):995-1000
references.pmid: 18098228
references.citation: Cold Spring Harb Symp Quant Biol. 2005;70:357-62
references.pmid: 16869772
references.citation: Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16
references.pmid: 15934498
references.citation: J Clin Oncol. 2008 Feb 10;26(5):786-90
references.pmid: 18258987